MedImmune, UMB ink $6 million research partnership
Wednesday, September 25, 2013
The deal spans five years, with all but $1 million of the bill footed by MedImmune. Under the agreement — the first of several planned for the Maryland biotech firm— MedImmune and UMB will undertake joint projects in the company's "core therapeutic areas," which include oncology, autoimmune and respiratory diseases. UMB is home to the University of Maryland BioPark.